John Kerr posted in clinical data • glaxosmithkline • GSK • off label • pharmaceuticals on July 3rd, 2012.
Pharmaceutical giant GlaxoSmithKline today announced it will plead guilty to marketing drugs for unapproved uses and failing to report safety data. In what is believed to be the largest ever US healthcare fraud settlement, the company will pay out US$3 billion in criminal fines and civil settlements. The multinational company was charged with violations of […]
Continue reading “GlaxoSmithKline concedes drug fraud charges”